Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin

References

• Lopez RN, Leach ST, Lemberg DA, et al. Fecal biomarkers in inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32:577–582.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793–798.
   PubMed Web of Science ®Google Scholar
• Manceau H, Chicha-Cattoir V, Puy H, et al. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474–483.
   PubMed Web of Science ®Google Scholar
• Amcoff K, Stridsberg M, Lampinen M, et al. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol. 2017;52:344–350.
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer PO, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108:83–89.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56–66.
   PubMedGoogle Scholar
• Dai C, Jiang M, Sun MJ, et al. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2018;33:990–997.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74–80.
   PubMed Web of Science ®Google Scholar
• Eklöf V, Löfgren-Burström A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017;141:2528–2536.
   PubMed Web of Science ®Google Scholar
• Samaan MA, Mosli MH, Sandborn WJ, et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465–1471.
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174–178.
   PubMed Web of Science ®Google Scholar
• Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402–408.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32–39.
   PubMed Web of Science ®Google Scholar
• Kok L, Elias SG, Witteman BJ, et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. Clin Chem. 2012;58:989–998.
   PubMed Web of Science ®Google Scholar
• McDonald PJ, Digby J, Innes C, et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis. 2013;15:e151–9.
   PubMed Web of Science ®Google Scholar
• Mowat C, Digby J, Strachan JA, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut. 2016;65:1463.
   PubMed Web of Science ®Google Scholar
• Högberg C, Karling P, Rutegård J, et al. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: the usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study. Scand J Gastroenterol. 2017;52:69–75.
   PubMed Web of Science ®Google Scholar
• Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017;7:2669.
   PubMed Web of Science ®Google Scholar
• Mooiweer E, Fidder HH, Siersema PD, et al. Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis. Inflamm Bowel Dis. 2014;20:1079–1084.
   PubMed Web of Science ®Google Scholar
• Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873–880.
   PubMed Web of Science ®Google Scholar
• Ryu DG, Kim HW, Park SB, et al. Assessment of disease activity by fecal immunochemical test in ulcerative colitis. WJG. 2016;22:10617–10624.
   PubMed Web of Science ®Google Scholar
• Inokuchi T, Kato J, Hiraoka S, et al. Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn’s disease. Inflamm Bowel Dis. 2016;22:1078–1085.
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Yamamoto T, Umegae S, et al. Faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease: a prospective study. Therap Adv Gastroenterol. 2017;10:577–587.
   PubMed Web of Science ®Google Scholar
• Shi HY, Chan FKL, Chan AWH, et al. Accuracy of faecal immunochemical test to predict endoscopic and histological healing in ulcerative colitis: a prospective study based on validated histological scores. J Crohns Colitis. 2017;11:1071–1077.
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Papamichael K, Christodoulou DK, et al. Histological healing beyond endoscopic healing in ulcerative colitis: shall we target the “ultra-deep” remission?. Dig Liver Dis. 2017;49:1332–1333.
   PubMedGoogle Scholar
• Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634–1640.
   PubMed Web of Science ®Google Scholar
• Park S, Abdi T, Gentry M, et al. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2016;111:1692–1701.
   PubMed Web of Science ®Google Scholar
• Iacucci M, Ghosh S. Mucosal healing – how deep is enough? Dig Dis. 2016;34:160–164.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8:927–935.
   PubMed Web of Science ®Google Scholar
• Rogler G, Vavricka S, Schoepfer A, et al. Mucosal healing and deep remission: what does it mean? World J Gastroenterol. 2013;19:7552–7560.
   PubMed Web of Science ®Google Scholar
• Carlsen K, Riis LB, Elsberg H, et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol. 2018;53:825–830.
   PubMed Web of Science ®Google Scholar